IJGII Inernational Journal of Gastrointestinal Intervention

pISSN 2636-0004 eISSN 2636-0012
ESCI

Article

home All Articles View

Original Article

Int J Gastrointest Interv 2020; 9(3): 106-110

Published online July 31, 2020 https://doi.org/10.18528/ijgii200019

Copyright © International Journal of Gastrointestinal Intervention.

The diagnostic yield of specimens obtained from endoscopic ultrasound guided fine needle biopsy of solid masses with the AcquireTM needle

Mark Bonnichsen1 , Ellie Skacel1 , James Kench2 , Arthur Kaffes1,3 , and Payal Saxena1,3,*

1AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, Australia
2Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, Australia
3Sydney Medical School, University of Sydney, Camperdown, Australia

Correspondence to:*AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Missenden Road, Camperdown NSW 2050, Australia.
E-mail address: psaxena1@jhmi.edu (P. Saxena).

Received: May 6, 2020; Revised: May 22, 2020; Accepted: May 22, 2020

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background: Recent developments in the design of needle tips used for fine needle biopsy via endoscopic ultrasound (EUS) allows for the procurement of core tissue for histological assessment in addition to cytology. Core tissue provides tissue architecture as well as the ability to perform molecular profiling investigations. We present a single centre study of experience with a new EUS needle with a Franseen tip (AcquireTM; Boston Scientific, Natick, MA, USA). The aim of the study was to assess the diagnostic yield of biopsies from solid lesions throughout the gastrointestinal tract.
Methods: We performed a retrospective study of consecutive patients undergoing EUS biopsy between January 2017 and November 2018. Cystic lesions with no solid component were excluded or if samples were not sent for both cytology and histology. Rapid onsite evaluation (ROSE) was performed and the core tissue obtained was sent for histology.
Results: Forty-six patients underwent EUS biopsy of solid lesions with specimens sent for both cytology and histology. Lesions included solid pancreatic masses (n = 31), lymph node (n = 3), gastric subepithelial lesion (n = 3), other (n = 9). The mean number of passes per lesion was 1.9 (range 1–4). In 43/46 (93%) of cases, a core specimen was obtained. Tissue obtained by EUS biopsy was adequate for evaluation by ROSE in 39/46 cases (85%). Histological diagnosis was confirmed in 41/46 (89%) cases compared to 31/46 (67%) cases with cytology (P = 0.011). Subgroup analysis of pancreatic lesions showed histological diagnosis was superior to cytology (90% vs 61%, P = 0.007). There were no adverse events.
Conclusion: Histological analysis of specimens obtained via EUS biopsy was superior to cytology, particularly in assessment of solid pancreatic lesions

Keywords: Endoscopic ultrasound, Fine needle biopsy, Solid lesions

Endoscopic ultrasound (EUS) has emerged as an important modality in the diagnosis and treatment of gastrointestinal diseases, especially in imaging of the pancreatobiliary system. The current method of obtaining biopsies through EUS is by fine needle aspiration (FNA). It is a minimally invasive and relatively safe procedure for obtaining tissue/cell samples inside gastrointestinal tract and surrounding organs such as the pancreas and local lymph nodes.1,2 This procedure is done by inserting a long needle through the accessory channel of an echoendoscope and is targeted into the organ of interest; cells are aspirated into a syringe with negative pressure attached to the opposite end of the needle.3,4

Recent developments in needle types have allowed the procurement of tissue with preserved architecture, suitable for histological evaluation. A Franseen tip (AcquireTM; Boston Scientific, Natick, MA, USA) end cutting needle with a crown shaped distal tip with three symmetrical bevelled cutting edges has recently become available. This design of the needle tip with multiple cutting surfaces provides more depth of insertion into the lesion to enable acquisition of more tissue specimens and maximize tissue capture.5 This also enhances stability and better control of the needle.6 Procurement of core tissue is preferred since it improves diagnostic accuracy and allows for more comprehensive molecular profiling investigations.7,8

The aim of the study was to assess the diagnostic yield of and histologic examination of biopsies performed with the new needle from solid lesions throughout the gastrointestinal tract comparing cytologic and histologic analysis. The secondary aim was to assess the adequacy rate of specimens obtained for analysis.

We performed a retrospective single centre study of patients undergoing EUS-fine needle biopsy (FNB) with the needle between January 2017 and November 2018. Ethics approval was granted via the Sydney Local Health District Ethics Committee (Approval number: X18-0445 & LNR/18/RPAH/638). Biopsies were performed using the 22 gauge AcquireTM needle via linear echoendoscope. All EUS procedures were performed by experienced endosonographers with multiple years of experience at performing high-volume EUS.

All procedures were performed using a linear array echoendoscope (Olympus America Corp., Center Valley, PA, USA) with patients in the left lateral decubitus position after administration of propofol or with the patient under general anesthesia. The technique used for tissue acquisition was as follows: no stylet used for the FNA, only 10 mL suction. Ten to fifteen to-and-fro movements were performed through the mass lesion. The same technique was used exclusively in this study for the sake of uniformity.9 Number of passes was at the discretion of the endoscopist. The primary outcome of the study was to assess the diagnostic yield of biopsies sent for cytology and histology from solid lesions throughout the gastrointestinal tract. A secondary outcome was to assess the adequacy rate of adequacy of specimens.

Patients were included if they were > 18 years of age and had a solid lesion identified that warranted biopsy. Patients were excluded if they were < 18 years of age, pregnant, or were undergoing EUS-guided biopsy of a cystic lesion. Diagnostic yield was defined as the percentage of patients biopsied in which a definitive diagnosis was made. Adequacy rate was defined as the percentage of patients biopsied in which the specimen was suitable for analysis but not necessarily able to make a definitive diagnosis.

Specimen processing

The specimen was expelled onto a slide using the stylet. If core tissue was apparent, it was expelled into a jar of formalin (Fig. 1). Any fluid material and core specimens were also expelled into Hank’s solution (ScienCell, Carlsbad, CA, USA).

Figure 1. Examples of tissue obtained from pancreas sampling obtained with AcquireTM needle. (A, B) Macroscopic image of sample acquired from core biopsy. (C–E) Cytology sample (Papanicolaou stain). Core sample showing pancreatic adenocarcinoma. Tumour thrombus evident in the venule (H&E stain).

Routine air-dried Diff-Quik stained smears were prepared at the time of aspiration for rapid onsite evaluation (ROSE) by experienced cytotechnologists. Wet-fixed (95% ethanol) smears were also prepared for later Papanicolaou staining and cytologic diagnosis. Aspirate material was placed in Hank’s solution for cell block preparation, which involved centrifugation of specimens at 2,000 Hz for 5 minutes followed by resuspension in human plasma and diluted thromboplastin/fibrinogen in a 1:3 mL ratio with distilled water. Cell blocks were then fixed in 3–5 mL of 10% neutral buffered formalin and placed in tissue cassettes for paraffin processing, microtomy and haematoxylin and eosin (H&E) staining. Standard 10% formalin fixation, paraffin embedding and H&E staining were used in processing the specimens for histologic examination. Immunohistochemistry studies were undertaken for evaluation of morphologically challenging lesions when required.

Statistical analysis

Continuous variables were expressed in median (interquartile range) as appropriate. Differences between subgroups were analysed using chi square test for categorical parameters. Statistical analysis was performed by Statistical Package for Social Science (SPSS ver. 22.0; IBM Corp., Armonk, NY, USA). A result was considered statistically significant if P < 0.05.

Over the study period, forty-six patients (52% male) underwent EUS biopsy of solid lesions. The patient characteristics are outlined in Table 1. The median age was 67.5 years. Lesions biopsied included solid pancreatic masses (n = 31) of which 27 (87%) were from the head or uncinate of pancreas, lymphadenopathy (n = 3), gastric subepithelial lesions (n = 3), other (including duodenal, mediastinal, and retroperitoneal lesions) (n = 9). The mean number of passes per lesion was 1.9 (range 1–4). In 43/46 (93%) of cases, a core specimen was obtained. Tissue obtained by EUS biopsy was adequate for evaluation by ROSE in 39/46 cases (85%) (Fig. 2, Table 2).

Table 1 . Patient Demographics (n = 46).

VariableValue
Sex
Male24 (52)
Female22 (48)
Median age, IQR (yr)67.5 (57–73.5)
Mean number of passes, range1.9 (1–4)
Indication for biopsy
Pancreatic mass (n = 31)
Head/uncinate process27 (87)
Body/tail4 (13)
Gastric mass3
Lymph node3
Other (duodenal lesion, mediastinal lesion, bile duct mass, retroperitoneal lesion)9

Values are presented as number (%) or number only unless otherwise indicated..

IQR, interquartile range..


Table 2 . Primary Outcome Group (Both Cytology and Histology Sent) (n = 46).

VariableCytologyHistologyP-value
Diagnostic yield31 (67)41 (89)0.011
Adequate sample39 (85)43 (93)0.18

Values are presented as number (%)..


Figure 2. Adequacy of specimen taken for assessment.

The primary outcome of tissue diagnosis could be achieved in 41/46 (89%) cases from the histology specimen alone compared to 31/46 (67%) cases with cytology (P = 0.011) (Fig. 3). Subgroup analysis of pancreatic lesions showed histological diagnosis was superior to cytology (90% vs 61%, P = 0.007) (Fig. 3, Table 3). In 7 cases, adenocarcinoma was missed on cytology but present in the histology sample.

Table 3 . Subgroup Analysis.

VariableCytologyHistologyP-value
Pancreatic lesions (n = 31)19 (61)28 (90)0.007
Non-pancreatic lesions (n = 15)12 (80)13 (87)0.624

Values are presented as number (%)..


Figure 3. (A) Diagnostic yield in all lesions (n = 46) (percentage of the samples in which a histological diagnosis was obtained). (B) Diagnostic yield of pancreatic lesions (n = 31) (percentage of the samples in which a histological diagnosis was obtained).

In the 5 cases where histology did not yield a diagnosis, 3 of the 5 cytology was also non-diagnostic. In one case the diagnosis confirmed on cytology was sarcoidosis and the other pancreatic cancer in which the core sample displayed necrosis with some atypical cells. In the 3 cases that were found to not have a diagnosis one patient underwent a distal pancreatectomy for a subsequently diagnosed neuroendocrine tumour, and two patients were lost to follow-up with no subsequent procedures for a pancreatic and gastric subepithelial lesion. There were no adverse events noted throughout the study period.

In the era of personalised treatments for malignancy, characterisation of tumour biology has become critical in determining tailor made treatments to improve outcomes, particularly when the prognosis from many upper gastrointestinal malignancies is poor.10,11 Procuring adequate core tissue samples for histology provides the ability to perform molecular investigations to further characterise tissue biology and aid in personalising treatment for patients. In obtaining accurate diagnosis, there is a preference by pathologists for histology rather than cytology specimens as the volume of neoplastic cells in aspirates alone is often insufficient for tumour marker analysis.1,2 ROSE has been previously thought to be a possible solution to increasing diagnostic yield from EUS specimens. ROSE, as opposed to histological analysis, requires the availability of an onsite cytopathologist, is not widely available and is often inaccessible after regular working hours. In addition, Wani et al12 in a randomised controlled trial in biopsy of pancreatic masses did not demonstrate a significant difference of ROSE in diagnostic yield of malignancy, proportion of adequate specimens or accuracy.

This study demonstrates that the AcquireTM needle was able to obtain samples suitable for core tissue analysis with the diagnostic yield close to 90%. Limited number of previous studies have shown the feasibility and safety of the AcquireTM needle with performance advantages over other available needles such as EchoTip ProCore (Wilson-Cook Medical Inc., Winston Salem, NC, USA) and SharkCore (Beacon Endoscopic, Newton, MA, USA).1315 Adler et al16 demonstrated a similar rate of histologic diagnosis with a mean number of passes of 3 compared to 2 in our study. In a study by Bang et al,6 the technical success rate of using the AcquireTM needle for EUS-FNB was 96.7% but an adverse event rate of 3.3%. Another study by Adler et al17 showed that tissue samples obtained through the AcquireTM needle was sufficient for histological diagnosis in 96% of cases and tissue cores were obtained in 71% of cases. The study by Al-Haddad et al5 revealed the diagnostic yield of the AcquireTM needle for ROSE was 94% and the diagnostic yield for histological assessment was 100%. This suggests our results are comparable to other studies and that tissue acquisition with the AcquireTM needle presents a promising solution to the issue of optimal handling of specimens obtained via EUS-FNB.

Histologic assessment was found to be significantly superior to cytological analysis, particularly when assessing pancreatic lesions. This finding adds to the body of evidence suggesting that the technique is not only safe but has a high rate of technical success in obtaining a suitable specimen and clinical success establishing a tissue diagnosis. Importantly, the alternative method of specimen processing (depositing in formalin) is a practical advantage for centers where ROSE is not available. Furthermore, single modality processing with formalin alone may have a cost benefit compared to ROSE where the presence of a technician is required.

The cytology diagnostic rate is lower than rates published in other studies and this may reflect that the AcquireTM needle is designed primarily for core tissue sampling. The finding of 7 malignancies that were missed on cytology suggests the value and importance of the ability of histology as a method of assessment for this indication. This provides evidence that the lack of availability of ROSE does not necessarily impair diagnostic accuracy.1820

The limitations of the study mainly relate to those inherent to retrospective studies in general. We are unable to assess the sensitivity and specificity as well as predictive values of the technique as not all patients with either positive or negative result underwent resection. Finally, the study was performed at an academic centre with experienced endosonographers with a high throughput of gastrointestinal pathology, with expert gastrointestinal pathologists, experienced in cytology and histopathology, and this also may affect the generalisability of these results to non-tertiary centres or those without access to ROSE.

In summary, histologic analysis of specimens obtained with an AcquireTM needle is superior to cytologic analysis. Centers where ROSE is not available may deposit their specimens directly into formalin with an expected high diagnostic yield rate. This finding whilst promising, requires validation in a larger sample size and for the growing list of indications of EUS-FNB in the gastrointestinal tract.

No potential conflict of interest relevant to this article was reported.

  1. Kim EJ, Sahai V, Abel EV, Griffith KA, Greenson JK, Takebe N, et al. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res. 2014;20:5937-45.
    Pubmed KoreaMed CrossRef
  2. Varadarajulu S, Hawes RH. The changing paradigm in EUS-guided tissue acquisition. Gastrointest Endosc Clin N Am. 2014;24:1-7.
    Pubmed CrossRef
  3. Kaffes AJ, Chen RY, Tam W, Norton I, Cho S, Devereaux B, et al. A prospective multicenter evaluation of a new side-port endoscopic ultrasound-fine-needle aspiration in solid upper gastrointestinal lesions. Dig Endosc. 2012;24:448-51.
    Pubmed CrossRef
  4. Fuccio L, Larghi A. Endoscopic ultrasound-guided fine needle aspiration: How to obtain a core biopsy? Endosc Ultrasound. 2014;3:71-81.
    Pubmed KoreaMed CrossRef
  5. Al-Haddad M, Patel K, Othman M. Su1320 prospective assessment of the performance of a new fine needle biopsy device at 2 large referral centers. Gastrointest Endosc. 2017;85(Suppl)):AB333.
  6. Bang JY, Hebert-Magee S, Hasan MK, Navaneethan U, Hawes R, Varadarajulu S. Endoscopic ultrasonography-guided biopsy using a Franseen needle design: initial assessment. Dig Endosc. 2017;29:338-46.
    Pubmed CrossRef
  7. Iglesias-Garcia J, Poley JW, Larghi A, Giovannini M, Petrone MC, Abdulkader I, et al. Feasibility and yield of a new EUS histology needle: results from a multicenter, pooled, cohort study. Gastrointest Endosc. 2011;73:1189-96.
    Pubmed CrossRef
  8. Jenssen C, Dietrich CF. Endoscopic ultrasound-guided fine-needle aspiration biopsy and trucut biopsy in gastroenterology- an overview. Best Pract Res Clin Gastroenterol. 2009;23:743-59.
  9. Saxena P, El Zein M, Stevens T, Abdelgelil A, Besharati S, Messallam A, et al. Stylet slow-pull versus standard suction for endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic lesions: a multicenter randomized trial. Endoscopy. 2018;50:497-504.
    Pubmed KoreaMed CrossRef
  10. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
    Pubmed CrossRef
  11. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012;62:118-28.
  12. Wani S, Mullady D, Early DS, Rastogi A, Collins B, Wang JF, et al. The clinical impact of immediate on-site cytopathology evaluation during endoscopic ultrasound-guided fine needle aspiration of pancreatic masses: a prospective multicenter randomized controlled trial. Am J Gastroenterol. 2015;110:1429-39.
    Pubmed CrossRef
  13. Mitri DR, Carrara S, Fabbri C, Mocciaro F, Repici A, Costamagna G, et al. Su1364 high yield of core tissue for histological analysis with high diagnostic accuracy of EUS-fine needle biopsy using the 22G acquire needle: a multicenter prospective study. Gastrointest Endosc. 2017;85(Suppl)):AB351.
  14. Adler DG, Witt B, Chadwick B, Wells J, Taylor LJ, Dimaio C, et al. Pathologic evaluation of a new endoscopic ultrasound needle designed to obtain core tissue samples: a pilot study. Endosc Ultrasound. 2016;5:178-83.
    Pubmed KoreaMed CrossRef
  15. DiMaio CJ, Kolb JM, Benias PC, Shah H, Shah S, Haluszka O, et al. Initial experience with a novel EUS-guided core biopsy needle (SharkCore): results of a large North American multicenter study. Endosc Int Open. 2016;4:E974-9.
    Pubmed KoreaMed CrossRef
  16. Adler DG, Muthusamy VR, Ehrlich DS, Parasher G, Thosani NC, Chen A, et al. A multicenter evaluation of a new EUS core biopsy needle: experience in 200 patients. Endosc Ultrasound. 2019;8:99-104.
    Pubmed KoreaMed CrossRef
  17. Adler DG, Taylor LJ, Muthusamy VR, Parasher G, Thosani N, Chen AM, et al. Su1319 clinical and pathologic evaluation of a new EUS core biopsy needle: a large multicenter trial. Gastrointest Endosc. 2017;85(Suppl)):AB333.
    CrossRef
  18. Attili F, Rimbaş M, Fantin A, Fabbri C, Carrara S, Di Maurizio L, et al. Performance of a new histology needle for EUS-guided fine needle biopsy: a retrospective multicenter study. Dig Liver Dis. 2018;50:469-74.
    Pubmed CrossRef
  19. Tian L, Tang AL, Zhang L, Liu XW, Li JB, Wang F, et al. Evaluation of 22G fine-needle aspiration (FNA) versus fine-needle biopsy (FNB) for endoscopic ultrasound-guided sampling of pancreatic lesions: a prospective comparison study. Surg Endosc. 2018;32:3533-39.
    Pubmed KoreaMed CrossRef
  20. Hébert-Magee S, Bae S, Varadarajulu S, Ramesh J, Frost AR, Eloubeidi MA, et al. The presence of a cytopathologist increases the diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration cytology for pancreatic adenocarcinoma: a meta-analysis. Cytopathology. 2013;24:159-71.